Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Silber

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zosterRichard Mills, Stephen K Tyring, Myron J Levin, et al.
Vaccine|January 26, 2007
Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adultsN Macaladad, T Marcano, M Guzman, et al.
Vaccine|May 13, 2015
Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroidsAmy F Russell, Janie Parrino, Chester L Fisher, et al.
The Journal of Infectious Diseases|February 23, 2010
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responsesAdriana Weinberg, Ann A Lazar, Gary O Zerbe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 1998
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 casesT J Walsh, J W Hiemenz, N L Seibel, et al.
European Journal of Gastroenterology & Hepatology|December 4, 2025
A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adultsJeffrey L Silber, Jason M Norman, Tokuwa Kanno, et al.
Annals of Internal Medicine|April 1, 1993
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trialD J Winston, P H Chandrasekar, H M Lazarus, et al.
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Infectious Diseases|January 23, 2010
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adultsDaniel M Musher, Susan B Manof, Charlie Liss, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zosterRichard Mills, Stephen K Tyring, Myron J Levin, et al.
Vaccine|January 26, 2007
Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adultsN Macaladad, T Marcano, M Guzman, et al.
Vaccine|May 13, 2015
Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroidsAmy F Russell, Janie Parrino, Chester L Fisher, et al.
The Journal of Infectious Diseases|February 23, 2010
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responsesAdriana Weinberg, Ann A Lazar, Gary O Zerbe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 1998
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 casesT J Walsh, J W Hiemenz, N L Seibel, et al.
European Journal of Gastroenterology & Hepatology|December 4, 2025
A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adultsJeffrey L Silber, Jason M Norman, Tokuwa Kanno, et al.
Annals of Internal Medicine|April 1, 1993
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trialD J Winston, P H Chandrasekar, H M Lazarus, et al.
Vaccine|December 8, 2010
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of ageFrancisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, et al.
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Pageof 7